Clinical trials: Transverse Myelitis
Vaccine Adverse Reaction
Transverse Myelitis Related to SARS-CoV-2 Vaccines
Few patients receiving SARS-CoV-2 vaccines may experience rare but serious adverse events such as transverse myelitis (TM). Today, data about TM are scarce.
- Trial name
- NCT05178264
- Testing
- SARS-CoV-2 vaccines
- Where
- France
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Sclerosis, Multiple, Neuromyelitis Optica Spectrum Disorder
French Registry for Monitoring Pregnancies for Multiple Sclerosis
The influence of pregnancy on the course of multiple sclerosis (MS) has long been a controversial topic. After the publication of the first large prospective study of pregnancy and MS in 1998, counselling of women with MS has…
- Conditions
- Sclerosis, Multiple, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders, Pregnancy Abnormal
- Trial name
- RESPONSE (NCT03900221)
- Testing
- No intervention
- Where
- 48 sites in France, Martinique
- Volunteers
- 1,500 people
- Sponsor
- Hospices Civils de Lyon
Neuromyelitis Optica Spectrum Disorder
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.
- Trial name
- NCT05314010
- Testing
- MIL62
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Interleukin-2 (IL-2) is an essential cytokine for T-cell proliferation. Low-dose IL-2 has been shown to increase the proportion of regulatory T cells (Tregs), negatively regulate effector T cells such as Th17 and Tfh cells, and…
- Trial name
- NCT07809724
- Testing
- IL-2 (interleukin 2)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Neuromyelitis Optica Spectrum Disorder
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria.
- Trial name
- NCT01845584
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Spinal Cord Injuries, Multiple Sclerosis
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT04721717
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Neuromyelitis Optica Spectrum Disease (NMOSD)
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07592754
- Testing
- KSVCBD injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chinese PLA General Hospital
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or…
- Trial name
- NCT05909761
- Testing
- UPLIZNA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Amgen
Multiple Sclerosis, Neuromyelitis Optica
The Italian Multiple Sclerosis and Related Disorders Register
The Italian Multiple Sclerosis and Related Disorders Register (Registro Italiano Sclerosi Multipla e Patologie Correlate - RISM) is an observational cohort study that aims to create an organised multicentre structure to collect…
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Diseases of the Central Nervous System, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- RISM (NCT07636876)
- Where
- Italy
- Volunteers
- 96,000 people
- Sponsor
- Fondazione Italiana Sclerosi Multipla
Neuromyelitis Optica Spectrum Disorder
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins…
- Trial name
- N-MOmentum LT (NCT06180278)
- Testing
- Blood tests, Inebilizumab
- Where
- 11 sites in United States, China and 5 more
- Volunteers
- 32 people
- Sponsor
- Amgen
NMO Spectrum Disorder, Azathioprine Adverse Reaction
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
Background: The pathogenesis of NMOSD has been linked to the cytokines interleukins (IL) -6, NOD-, LRR-and pyrin domain-containing 3 (NLRP3) and IL-18 that contribute to development of inflammatory reactionsmay.
- Trial name
- NCT05896605
- Testing
- Azathioprine
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility.
- Conditions
- Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis, Autoimmune Encephalitis, Myasthenia Gravis
- Trial name
- RANID (NCT07653984)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Devic's Disease
Hematopoietic Stem Cell Transplant in Devic's Disease
This study is designed to examine whether treating Devic's disease patients with high dose cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which reduce the function of the immune system)…
- Trial name
- NCT00787722
- Testing
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Northwestern University
Neuromyelitis Optica Spectrum Disorder Attack
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG).
- Trial name
- EASE-NMO (NCT06673394)
- Testing
- Complement protein C5 inhibitor, IVMP
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility
CONTEXT A desire for pregnancy is common in young patients with multiple sclerosis (MS). The impact of MS on women fertility is debated, and the impact of disease-modifying therapies (DMTs) on fertility is not well known.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Fertility
- Trial name
- FERTIMUS (NCT07164924)
- Testing
- blood sample to analyse AMH level on the serum
- Where
- 27 sites in France, Martinique
- Volunteers
- 800 people
- Sponsor
- University Hospital, Clermont-Ferrand
Neuromyelitis Optica
Neuromyelitis Optica (NMO) & Cetirizine
Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability.
- Trial name
- NCT02865018
- Testing
- cetirizine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Neuromyelitis Optica Spectrum Disorder, NMOSD
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT).
- Conditions
- Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
- Trial name
- NCT05966467
- Where
- 33 sites in United States, Argentina and 6 more
- Volunteers
- 200 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Ublituximab (also known as LFB-R603) is a monoclonal antibody that specifically binds to the trans-membrane antigen CD20. The binding induces immune response that causes lysis of B cells.
- Trial name
- NCT02276963
- Testing
- Ublituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Neuromyelitis Optica Spectrum Disorders (NMOSD)
HANDLE-a Real World Study on Satralizumab in NMOSD
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting…
- Trial name
- NCT06829524
- Testing
- Satralizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital